Xeris Biopharma Holdings, Inc. XERS Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $2.23M+124% | $11.08M+317% | $621K+104% | -$1.93M+87.2% | -$9.22M+51.4% | ||
| $337K+7.0% | $335K+7.0% | $338K+10.1% | $325K+15.7% | $315K-3.4% | ||
| $4.14M-6.8% | $5.27M+46.6% | $7.64M+12.9% | $5.01M+18.3% | $4.44M+17.9% | ||
| $889K+5.3% | $866K+5.1% | $800K0.0% | $800K0.0% | $844K+47.3% | ||
| $5.25M-11.3% | —— | $703K— | $6.72M+33.7% | $5.92M+432% | ||
| -$851K-124% | $4.01M+27.9% | $4.09M+290% | $7.57M+234% | $3.62M+55.1% | ||
| $4.25M+4.6% | -$1.7M+67.4% | $2M— | -$4.43M-178% | $4.06M+191% | ||
| -$1.5M+82.6% | $3.7M-12.9% | —— | —— | -$8.58M-664% | ||
| -$4.68M-445% | $2.34M+169% | $297K-36.7% | $0-100% | $1.36M+69.6% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$145K+90.5% | —— | $5.15M— | -$270K— | -$1.53M-183% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| $163K+38.1% | $151K+38.5% | $140K+32.1% | $128K-21.5% | $118K-33.3% | ||
| -$434K-23.3% | -$422K— | -$412K-215% | -$390K-229% | -$352K-146% | ||
| $9.87M+198% | $20.04M— | $18.43M+322% | $182K+102% | -$10.03M+50.6% | ||
| -$325K-2,400% | -$333K-103% | -$71K— | -$279K— | -$13K+99.9% | ||
| $847K-82.6% | $584K+227% | $5.16M— | $972K— | $4.86M+959% | ||
| $17.02M+113% | $1.54M+828% | $478K+476% | $860K+1,586% | $8M+133% | ||
| -$8.84M-182% | —— | $13.85M— | —— | -$3.14M-109% | ||
| $708K+105% | $19.44M+56.9% | $32.21M+2,011% | $845K+117% | -$13.18M-177% | ||
| $5.35M— | $6.95M+15.4% | $7.08M-43.8% | $13.09M+92.0% | $0-100% | ||
| $889K+5.3% | $866K+5.1% | $800K0.0% | $800K0.0% | $844K+47.3% | ||
| $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | $2.71M0.0% | ||
| -$246K-140% | —— | —— | —— | $622K-49.1% | ||
| $6.26M+279% | —— | $11.93M+533% | $6.8M+850% | $1.65M+301% | ||
| -$434K-23.3% | -$422K— | -$412K-215% | -$390K-229% | -$352K-146% | ||
| -$145K+90.5% | —— | $5.15M— | -$270K— | -$1.53M-183% | ||
| $163K+38.1% | $151K+38.5% | $140K+32.1% | $128K-21.5% | $118K-33.3% | ||
| -$325K-2,400% | -$333K-51.4% | -$71K+18.4% | -$279K+29.7% | -$13K+92.1% | ||
| -$434K-23.3% | -$422K— | -$412K-215% | -$390K-229% | -$352K-146% | ||
| $7.33M— | —— | —— | —— | $0— | ||
| $0-100% | —— | —— | $11.96M— | $3.19M— | ||
| $0-100% | —— | $22K— | $180K— | $99K— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Xeris Biopharma Holdings, Inc. generate?
- Xeris Biopharma Holdings, Inc. (XERS) generated $48.5M in operating cash flow over the trailing twelve months.
- Where does Xeris Biopharma Holdings, Inc.'s cash flow data come from?
- Every line is extracted from Xeris Biopharma Holdings, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
